Mitophagy-Modulating Compositions for OPA1 and SLSMD Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for mitochondrial diseases, such as OPA1 disease and Single Large-Scale Mitochondrial DNA Deletion (SLSMD) syndromes, are inadequate in addressing the underlying mitochondrial dysfunction and associated symptoms due to impaired or aberrant mitophagy.
Innovation Solution
Compositions comprising specific agents like folinic acid, lithium chloride, metformin, resveratrol, and others, administered separately or in combination, modulate mitophagy, mitochondrial stress, and mtDNA heteroplasmy levels to treat mitochondrial diseases, including OPA1 disease and SLSMD syndromes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for mitochondrial diseases, then patients receive standard care, but the underlying mitochondrial dysfunction and associated symptoms are not adequately addressed
Solution Approach 1:
The patent applies parameter changes by modulating mitophagy levels through various compounds and interventions. Specifically, it adjusts the rate of mitochondrial degradation to optimize mitochondrial function in diseases where mitophagy is either impaired or aberrant. This involves changing the physiological parameter of mitophagy flux to restore proper mitochondrial quality control and address underlying dysfunction.
Solution Approach 2:
The patent uses mitophagy modulation as an intermediary mechanism to treat mitochondrial diseases. By introducing compounds that regulate mitophagy (such as those affecting PINK1, PARK2, or other mitophagy pathway components), the treatment indirectly restores mitochondrial function without directly targeting the primary mitochondrial defect. This intermediary approach allows treatment of downstream effects while addressing root causes.
2Reliability
If mitophagy is impaired or aberrant in mitochondrial diseases, then mitochondrial quality control is compromised, but standard treatments cannot restore proper mitophagy function
Solution Approach 1:
The patent changes the parameter of mitophagy activity by administering compounds that specifically modulate mitophagy pathways. In diseases with impaired mitophagy, the treatment increases mitophagy flux to restore quality control. This is achieved through compounds that activate mitophagy regulators or bypass defective components, effectively adjusting the mitophagy parameter back to physiological levels.
Solution Approach 2:
The patent applies preliminary action by restoring mitophagy function before addressing other aspects of mitochondrial dysfunction. By first reestablishing proper mitochondrial quality control through mitophagy modulation, the treatment creates a foundation for subsequent therapeutic interventions. This preliminary restoration of quality control mechanisms prepares the system for further treatment of specific mitochondrial defects.
3Reliability
If multiple agents are used to modulate mitophagy, then therapeutic efficacy is improved, but treatment complexity increases
Solution Approach 1:
The patent merges multiple therapeutic agents into combination regimens that target different aspects of mitophagy regulation. By combining compounds that act on different components of the mitophagy pathway (e.g., agents affecting PINK1, PARK2, and other regulators), the treatment achieves synergistic effects that improve therapeutic efficacy while addressing multiple defects simultaneously.
Solution Approach 2:
The patent employs compounds with multi-functionality that can modulate mitophagy through multiple mechanisms. Some agents affect both upstream signaling and downstream execution of mitophagy, or simultaneously influence mitophagy and other mitochondrial functions. This multi-functionality allows single agents or simplified combinations to address complex pathological processes.
Data Source
AI summary
Compositions and methods for modulation by upregulation (up modulation) and/or downregulation (down modulation) of mitophagy are described for the treatment of mitochondrial disorders including OPA-1 related disease and Single Large Scale Mitochondrial DNA Deletion (SLSMD). Also disclosed are a number of screening assays and gene targets having utility for the identification of agents which modulate the phenotype associated with such disorders.